Bright Minds closes $175-million (U.S.) public offering

Mr. Alex Vasilkevich reports BRIGHT MINDS BIOSCIENCES ANNOUNCES CLOSING OF US$175 MILLION PUBLIC OFFERING Bright Minds Biosciences Inc. has closed its recently announced public offering of 1,945,000 common shares in the capital of the company at a price of $90.00 (U.S.) per common share for gross proceeds of $175.05-million (U.S.). In connection with the offering, the company has granted the underwriters a 30-day option to purchase up to an additional 291,750 common shares at the public offering price, less underwriting discounts and commissions. All of the securities sold in this offering were offered by Bright Minds. The company intends to use the net proceeds from the offering to finance future clinical trials for the company's drug candidates, including for absence seizures, DEE and Prader-Willi Syndrome, as well as initiation of phase 1 clinical drug trials for BMB-105, and additional research and development work on earlier phase programs, as well as for general corporate and working capital purposes. Jefferies, TD Cowen, Piper Sandler & Co. and Cantor acted as joint book-running managers for the offering. The company has filed a shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission (SEC) which was declared effective by the SEC on Sept. 2, 2025. The offering was made solely by means of a prospectus and a prospectus supplement that form a part of the registration statement. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained for free by visiting EDGAR on the SEC website, or from (i) Jefferies LLC, attention: equity syndicate prospectus department, 520 Madison Ave., New York, N.Y., 10022, by telephone at 877-821-7388 or by e-mail at [email protected], (ii) TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Ave., Edgewood, N.Y., 11717, or by e-mail at [email protected], (iii) Piper Sandler & Co., attention: prospectus department, 350 North 5th St., suite 1000, Minneapolis, Minn., 55401, or by telephone at 800-747-3924, or by e-mail at [email protected], or (iv) Cantor Fitzgerald & Co., attention: capital markets, 110 East 59th St., sixth floor, New York, N.Y., 10022, or by e-mail at [email protected]. About Bright Minds Biosciences Inc. Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. The company's pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives. Bright Minds has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry. We seek Safe Harbor.